Abstract
Prostaglandins serve as the connecting link between inflammation and cancer. mPGES1, the downstream enzyme in the prostaglandin pathway is considered a better target than COX-2 against the progression of cancer due to the cardiovascular and other complications associated with the inhibition of the latter. Despite the discovery of several compounds that inhibit mPGES1 none could enter the market as drugs because of the problems concerning specificity and unacceptable pharmacokinetic properties. Expression of mPGES1 is inducible in conditions of inflammation and hypoxia and its expression is regulated by a number of transcriptional factors. Targeting these transcription factors could be an alternative approach in the drug discovery process. In this review, the characteristics of the transcription factors, their ability to bind to the promoter of mPGES1 gene and the inhibitors against them have been discussed. The Structure Activity Relationship of the reported inhibitors is highlighted. Finally, practical challenges to further the drug development and future research directions are discussed. These novel compounds that are inhibitors of the major transcription factors are promising candidates for further development as inhibitors of mPGES1.
Keywords: Cancer, inflammation, inhibitors, prostaglandin E synthase, transcription factors.
Current Drug Targets
Title:Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Volume: 18 Issue: 1
Author(s): Meera Ramanan and Mukesh Doble
Affiliation:
Keywords: Cancer, inflammation, inhibitors, prostaglandin E synthase, transcription factors.
Abstract: Prostaglandins serve as the connecting link between inflammation and cancer. mPGES1, the downstream enzyme in the prostaglandin pathway is considered a better target than COX-2 against the progression of cancer due to the cardiovascular and other complications associated with the inhibition of the latter. Despite the discovery of several compounds that inhibit mPGES1 none could enter the market as drugs because of the problems concerning specificity and unacceptable pharmacokinetic properties. Expression of mPGES1 is inducible in conditions of inflammation and hypoxia and its expression is regulated by a number of transcriptional factors. Targeting these transcription factors could be an alternative approach in the drug discovery process. In this review, the characteristics of the transcription factors, their ability to bind to the promoter of mPGES1 gene and the inhibitors against them have been discussed. The Structure Activity Relationship of the reported inhibitors is highlighted. Finally, practical challenges to further the drug development and future research directions are discussed. These novel compounds that are inhibitors of the major transcription factors are promising candidates for further development as inhibitors of mPGES1.
Export Options
About this article
Cite this article as:
Ramanan Meera and Doble Mukesh, Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450117666160826093137
DOI https://dx.doi.org/10.2174/1389450117666160826093137 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry Chemical Constituents and Biological Activities of Vietnamese Medicinal Plants
Current Topics in Medicinal Chemistry Synthesis and Anticancer Activity of 2-Aryl-6-diethylaminoquinazolinone Derivatives
Letters in Drug Design & Discovery New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry A Computer-Based Approach to the Rational Discovery of New Trichomonacidal Drugs by Atom-Type Linear Indices
Current Drug Discovery Technologies Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)
Current Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Elucidation of Pathophysiology and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells
Current Cancer Drug Targets Development of Natural Bioactive Alkaloids: Anticancer Perspective
Mini-Reviews in Medicinal Chemistry Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Cytology for the Detection of Early Recurrence of Gynecologic Cancer in the Vaginal Vault
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery